(VIANEWS) – Shares of Xenetic Biosciences (NASDAQ: XBIO) rose by a staggering 27.24% in 21 sessions from $3.23 at 2023-06-21, to $4.11 at 14:39 EST on Thursday, after three consecutive sessions in a row of gains. NASDAQ is falling 1.47% to $14,146.56, after three sequential sessions in a row of gains.
Xenetic Biosciences’s last close was $3.93, 60.72% under its 52-week high of $10.00.
About Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-4.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.06%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Xenetic Biosciences’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
Xenetic Biosciences’s stock is valued at $4.11 at 14:39 EST, way under its 52-week high of $10.00 and way higher than its 52-week low of $2.40.
Moving Average
Xenetic Biosciences’s worth is way higher than its 50-day moving average of $3.38 and below its 200-day moving average of $4.32.
Volume
Today’s last reported volume for Xenetic Biosciences is 8753 which is 74.9% below its average volume of 33663.
More news about Xenetic Biosciences (XBIO).
